Celltrion to delist 2.75% convertibles after conversion, redemption

By Susanna Moon

Chicago, March 28 – Celltrion, Inc. announced the conversion or redemption of all of its $300 million 2.75% convertible bonds due 2018.

The convertibles were called because the outstanding amount was less than the 10% of the principal amount originally issued as of Feb. 1, according to a company notice.

Holders either converted their bonds into shares or received the principal amount plus accrued interest, the filing noted.

As of March 16, none of the bonds were left outstanding and the company said it will delist the convertibles.

Celltrion is a biopharmaceutical company based in Incheon, South Korea.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.